⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Retatrutide (Retatrutide) | Accelerate Your Fibrosis Research

Home/Drugs/Retatrutide

Retatrutide

Retatrutide

Phase 3

Sponsor: Eli Lilly

Indication: MASH / Obesity

Mechanism of Action

Triple Agonist (GLP-1/GIP/Glucagon)

Target: GLP-1Target: GIPTarget: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06039826

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Phase:PHASE1Org:Eli Lilly and Company

COMPLETED

Relevant Publications (PubMed)

Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.

Raza SS, Zakir Z, Hashmat A et al.

Cureus2025 Nov

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.

Martínez-Castelao A, Górriz JL, Fernández-Fernández B et al.

J Clin Med2025 Nov 23

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.

Abdelrahman RM, Musa TH, Arbab IA et al.

J Obes2025

Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.

Validated Models

This drug has been validated in the following preclinical models:

NCT06003465

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

Phase:PHASE1Org:Eli Lilly and Company

COMPLETEDNCT05548231

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Phase:PHASE1Org:Eli Lilly and Company

COMPLETEDNCT04823208

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Phase:PHASE1Org:Eli Lilly and Company

ACTIVE_NOT_RECRUITINGNCT06859268

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Phase:PHASE3Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov

Takrori E, Peshin S, Singal S

Medicina (Kaunas)2025 Nov 5

Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders.

Cho YK, Jung CH

Clin Mol Hepatol2025 Nov 26

View more on PubMed